A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)

This study tests a triple-target CAR-T cell therapy — which is engineered to attack three proteins on cancer cells (CD19, CD22, and BCMA) simultaneously — in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (a type of blood cancer) that has stopped responding to standard treatment. **You may be eligible if...** - You have confirmed relapsed or refractory B-cell non-Hodgkin lymphoma (including DLBCL, PMBCL, transformed follicular lymphoma, or high-grade B-cell lymphoma) - Your cancer did not respond to or relapsed after standard treatments including anti-CD20 therapy and chemotherapy - At least two of the three target proteins (CD19, CD22, BCMA) are present on your cancer cells - You are in good health (ECOG 0–1) with a life expectancy of at least 12 weeks - Your heart, kidney, and liver function are within acceptable ranges **You may NOT be eligible if...** - You have received certain prior therapies that could interfere - You have active, uncontrolled infections or severe organ dysfunction - You have recently had a stem cell transplant Talk to your doctor to see if this trial is right for you.